{"page_content": "Pipeline\nSeagen is developing and advancing a new generation of targeted treatments to advance \ncancer care. We designed our pipeline with our patients in mind, focusing on therapies that \nhave the potential to address significant unmet medical needs.\nRESEARCH IN DEVELOPMENT MARKETED2021/2022 Research  \nAreas of Focus\n\u2022 Proprietary ADC technologies\n\u2022 Immunotherapies to innate and adaptive \nimmune targets\n\u2022 New classes of ADCs that incorporate novel \nsmall molecule payloads designed to kill \ntumor cells and induce an anti-tumor \nimmune response\n\u2022 Novel antibody engineering technologies\n\u2022 ADCs in combination with checkpoint \ninhibitors\n\u2022 Additional targeted cancer therapeutics Early-Stage Pipeline Assets\nLate-Stage Pipeline Assets\nADC Technology\n\u2022 Ladiratuzumab vedotin\n\u2022 Disitamab vedotinApproved Products\n\u2022 ADCETRIS: Foundation of \ncare of CD30-expressing \nlymphomas\n\u2022 PADCEV : First-in-class \nADC for urothelial cancer\n\u2022 TUKYSA: Best-in-class TKI \nfor HER2+ breast cancer\n\u2022 TIVDAK: First-in-class ADC \nfor cervical cancerSEA Technology\n\u2022 SEA-CD40\n\u2022 SEA-TGT\n\u2022 SEA-BCMA\n\u2022 SEA-CD70ADC Technology\n\u2022 SGN-CD228A\n\u2022 SGN-B6A\n\u2022 SGN-STNV\n\u2022 SGN-PDL1V\n\u2022 SGN-B7H4V\n\u2022 SGN-ALPV\nABOUT THIS REPORT\nPERFORMANCE DATA SUMMARYINNOVATION FOR A SUSTAINABLE FUTURE\nPATIENT AND COMMUNITY CARE\nEMPLOYEE EMPOWERMENT\nRESPONSIBLE STEWARDSHIP\n 13", "metadata": {"source": "NASDAQ_SGEN_2022.pdf", "page": 12, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}